Form 4: Kyverna Therapeutics Director Beth Seidenberg Reports New Equity Grants and Indirect Holdings

Kyverna Therapeutics, Inc. Director and 10% owner Beth C. Seidenberg reported the acquisition of 16,634 restricted stock units and 65,351 stock options, alongside significant indirect holdings, as part of a recent SEC Form 4 filing.

Summary

• Beth C. Seidenberg, a Director and 10% owner of Kyverna Therapeutics, Inc. (KYTX), reported new equity grants on May 29, 2025.
• The grants include 16,634 shares of common stock as a restricted stock unit (RSU) award, acquired at a price of $0.
• Additionally, 65,351 stock options were granted with an exercise price of $2.63 per share, also acquired at a price of $0.
• Both the RSU award and the stock options are set to vest in full on the earlier of May 29, 2026, or immediately prior to the Issuer's 2026 annual meeting of stockholders, contingent on continuous service.
• Following these transactions, Ms. Seidenberg directly holds 16,634 shares of common stock and 65,351 stock options.
• Ms. Seidenberg also indirectly beneficially owns 3,787,940 shares of common stock through Westlake BioPartners Fund I, L.P. and 735,984 shares through Westlake BioPartners Opportunity Fund I, L.P.
• As managing director of the general partners for both Westlake funds, Ms. Seidenberg has sole voting and dispositive control but disclaims beneficial ownership except to the extent of her pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grants are standard compensation and align insider interests with the company's long-term performance, which is generally viewed favorably. There are no negative implications or significant risks disclosed.

Positives

• The grants of restricted stock units and stock options align the director's interests with long-term shareholder value through future vesting conditions.
• The acquisition of equity by a director and 10% owner can signal continued confidence in the company's future prospects.

Future Outlook

The document indicates future vesting events for the granted equity, contingent on the reporting person's continuous service to the Issuer through May 29, 2026, or the 2026 annual meeting.

Industry Context

This Form 4 filing reflects a standard compensation practice for directors and significant shareholders in the biotechnology or pharmaceutical industry, where equity grants are common to incentivize long-term commitment and align interests with company performance.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a common compensation mechanism in the biotech industry, similar to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their board members.
• The vesting schedule, tied to continued service and a specific future date or annual meeting, is a standard approach to retain key personnel and align their incentives with the company's long-term success, comparable to equity incentive plans seen across the S&P 500.

Related Party Transactions

• Beth C. Seidenberg's indirect beneficial ownership through Westlake BioPartners Fund I, L.P. and Westlake BioPartners Opportunity Fund I, L.P. represents holdings by entities where she serves as managing director of their general partners, indicating a related party relationship through investment funds.

Stakeholder Impact

• Shareholders: The equity grants align the director's incentives with shareholder interests, potentially fostering long-term value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted stock units and stock options are scheduled to vest on the earlier of May 29, 2026, or immediately prior to the Issuer's 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Kyverna Therapeutics, KYTX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, Westlake BioPartners